Cargando…

Efficacy and safety of adding evogliptin versus sitagliptin for metformin‐treated patients with type 2 diabetes: A 24‐week randomized, controlled trial with open label extension

AIMS: This trial consisted of a 24‐week multicentre, randomized, double‐blind, double‐dummy, active‐controlled study and a 52‐week open label extension study to assess the efficacy and safety of evogliptin, a novel dipeptidyl peptidase‐4 inhibitor, compared to sitagliptin in patients with type 2 dia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, Sang‐Mo, Park, Cheol‐Young, Hwang, Dong‐Min, Han, Kyung Ah, Lee, Chang Beom, Chung, Choon Hee, Yoon, Kun‐Ho, Mok, Ji‐Oh, Park, Kyong Soo, Park, Sung‐Woo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412933/ https://www.ncbi.nlm.nih.gov/pubmed/28058750 http://dx.doi.org/10.1111/dom.12870

Ejemplares similares

Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension
por: Moon, Jun Sung, et al.
Publicado: (2023)

Effect of Rifampicin on the Pharmacokinetics of Evogliptin in Healthy Volunteers
por: Shin, Yesong, et al.
Publicado: (2022)

Efficacy and safety of evogliptin treatment in patients with type 2 diabetes: A multicentre, active‐controlled, randomized, double‐blind study with open‐label extension (the EVERGREEN study)
por: Kim, Gyuri, et al.
Publicado: (2020)

The Effect of Evogliptin Tartrate on Controlling Inflammatory Pain
por: Cho, Pyung Goo, et al.
Publicado: (2023)

Effects of the Antidiabetic Drugs Evogliptin and Sitagliptin on the Immune Function of CD26/DPP4 in Th1 Cells
por: Yoon, Hyunyee, et al.
Publicado: (2021)

Efficacy and safety of evogliptin monotherapy in patients with type 2 diabetes and moderately elevated glycated haemoglobin levels after diet and exercise
por: Park, Juri, et al.
Publicado: (2017)

Pharmacokinetic and pharmacodynamic drug–drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers
por: Kim, Dasohm, et al.
Publicado: (2023)

Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes
por: Ferrannini, Ele, et al.
Publicado: (2013)

Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats
por: Sharma, Ashish Kumar, et al.
Publicado: (2012)

The Effect of Compression Pressure on the First Layer Surface Roughness and Delamination of Metformin and Evogliptin Bilayer and Trilayer Tablets
por: Kim, Sun Ho, et al.
Publicado: (2023)

Efficacy of evogliptin and cenicriviroc against nonalcoholic steatohepatitis in mice: a comparative study
por: Wang, Zheng, et al.
Publicado: (2019)

Sitagliptin added to stable insulin therapy with or without metformin in Chinese patients with type 2 diabetes
por: Shankar, R Ravi, et al.
Publicado: (2016)

Efficacy and safety of ipragliflozin as an add‐on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial
por: Han, Kyung‐Ah, et al.
Publicado: (2018)

Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects
por: Rhee, Su-jin, et al.
Publicado: (2016)

Effects of Evogliptin as Add on in Type 2 Diabetes (T2DM) Subjects Inadequately Controlled With Metformin and Glimepiride Combination
por: Guha, Shaibal
Publicado: (2021)

Spectroflourometric and Spectrophotometric Methods for the Determination of Sitagliptin in Binary Mixture with Metformin and Ternary Mixture with Metformin and Sitagliptin Alkaline Degradation Product
por: El-Bagary, Ramzia I., et al.
Publicado: (2011)

Comparative Study on Adding Pioglitazone or Sitagliptin to Patients with Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin
por: Jameshorani, Maryam, et al.
Publicado: (2017)

Evogliptin Suppresses Calcific Aortic Valve Disease by Attenuating Inflammation, Fibrosis, and Calcification
por: Choi, Bongkun, et al.
Publicado: (2021)

Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects
por: Hwang, Inyoung, et al.
Publicado: (2020)

Evogliptin Directly Inhibits Inflammatory and Fibrotic Signaling in Isolated Liver Cells
por: Seo, Hye-Young, et al.
Publicado: (2022)

Sustained 52‐week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes
por: Handelsman, Yehuda, et al.
Publicado: (2019)

Comparative Efficacy of Adding Sitagliptin to Metformin, Sulfonylurea or Dual Therapy: A Propensity Score-Weighted Cohort Study
por: Mamza, Jil, et al.
Publicado: (2015)

Efficacy and safety of sitagliptin added to metformin and insulin compared with voglibose in patients with newly diagnosed type 2 diabetes
por: Shi, Chunhong, et al.
Publicado: (2019)

Four-Year Durability of Initial Combination Therapy with Sitagliptin and Metformin in Patients with Type 2 Diabetes in Clinical Practice; COSMIC Study
por: Ku, Eu Jeong, et al.
Publicado: (2015)

Improved Chromatographic Separation of Sitagliptin Phosphate and Metformin Hydrochloride
por: Hendy, Moataz S.
Publicado: (2015)

Protective Effects of Evogliptin on Steatohepatitis in High-Fat-Fed Mice
por: Kim, Jin Hyun, et al.
Publicado: (2020)

Effects of Dapagliflozin Compared with Sitagliptin and Metformin in Drug-Naïve Japanese Patients with Type 2 Diabetes: A 12-Week, Open-Label, Randomized, Active-Controlled Trial
por: Ito, Daisuke, et al.
Publicado: (2021)

Effects of the Combination of Evogliptin and Leucine on Insulin Resistance and Hepatic Steatosis in High-Fat Diet-Fed Mice
por: Shin, Chang Yell, et al.
Publicado: (2021)

New combination treatments in the management of diabetes: focus on sitagliptin – metformin
por: Green, Jennifer, et al.
Publicado: (2008)

Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects
por: Yoo, Hyounggyoon, et al.
Publicado: (2020)

Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks
por: Kadowaki, Takashi, et al.
Publicado: (2012)

A 52‐week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N‐ISM study
por: Kitazawa, Masaru, et al.
Publicado: (2021)

Efficacy and safety of combination of empagliflozin and metformin with combination of sitagliptin and metformin during Ramadan: an observational study
por: Ahmed, Ibrar, et al.
Publicado: (2022)

Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26‐week, open‐label, randomized, active comparator clinical trial
por: Zang, L., et al.
Publicado: (2016)

Lobeglitazone and pioglitazone as add‐ons to metformin for patients with type 2 diabetes: a 24‐week, multicentre, randomized, double‐blind, parallel‐group, active‐controlled, phase III clinical trial with a 28‐week extension
por: Jin, S.‐M., et al.
Publicado: (2015)

Hypoglycemia associated with off-label sitagliptin use
por: Whitley, Heather P, et al.
Publicado: (2008)

Evogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice
por: Kim, Mi-Jin, et al.
Publicado: (2020)

Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
por: Reynolds, Jonathan K
Publicado: (2009)

Papulonodular Lesions in a Patient of Diabetes Mellitus Receiving Sitagliptin and Metformin
por: Agrawal, Prabhat, et al.
Publicado: (2021)

Bioequivalence Evaluation in Healthy Volunteers: New Generic Formulations of Sitagliptin and Sitagliptin–Metformin Fixed-Dose Combination Compared with the Originator Products
por: Schnaars, Yvonne, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hc9u3to25upi8s9kg8fum4serq